Johnson & Johnson retracts sales forecast for COVID-19 vaccines
The company cites demand uncertainty and global oversupply. The company previously released its Q1 2022 quarterly report.
Johnson & Johnson noted that its COVID-19 vaccine sales contributed to the company's growth. However, lower sales of Remicade, an inflammatory disease treatment, played the opposite role.